Mirza Metita, Yorihisa Kitagawa, H. Shimada, H. Nakashizuka
{"title":"息肉样脉络膜血管病","authors":"Mirza Metita, Yorihisa Kitagawa, H. Shimada, H. Nakashizuka","doi":"10.35479/IJRETINA.2018.VOL001.ISS002.46","DOIUrl":null,"url":null,"abstract":"Introduction: to report a case of PCV that has been successfully treated with intravitreal injection of t-PA, ranibizumab, and pneumatic displacement. \nMethod: A 65 years old man presented with blurred vision of his right eye. No systemic abnormalities were found. Initial visual acuity RE was 6/18. Funduscopy examination showed submacular hemorrhage in posterior pole. OCTA, FA and ICG confirmed the diagnosis of PCV. We performed anterior chamber paracentesis and intravitreal injection of 0,05 ml t-PA, 0,05 ml ranibizumab, and 0,3 ml 100% C3F8 at a time in retrobulbar anesthesia. The patient was instructed to maintain face down positioning for 2 days. \nResults: We evaluated the visual acuity, central retinal thickness (CRT), and central pigment epithelial detachment (PED) thickness for 2 years. The visual acuity was increasing gradually from 6/18 to 6/6 in the first year. The hemorrhage was displaced completely, the CRT and central PED thickness were decreased. In the second year the patient had recurrence of PCV with serous retinal detachment and treated with intravitreal aflibercept. \nConclusion: Combined treatment of intravitreal t-PA, ranibizumab, and C3F8 can be used as a beneficial therapy for PCV.","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"91 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Polypoidal Choroidal Vasculopathy\",\"authors\":\"Mirza Metita, Yorihisa Kitagawa, H. Shimada, H. Nakashizuka\",\"doi\":\"10.35479/IJRETINA.2018.VOL001.ISS002.46\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: to report a case of PCV that has been successfully treated with intravitreal injection of t-PA, ranibizumab, and pneumatic displacement. \\nMethod: A 65 years old man presented with blurred vision of his right eye. No systemic abnormalities were found. Initial visual acuity RE was 6/18. Funduscopy examination showed submacular hemorrhage in posterior pole. OCTA, FA and ICG confirmed the diagnosis of PCV. We performed anterior chamber paracentesis and intravitreal injection of 0,05 ml t-PA, 0,05 ml ranibizumab, and 0,3 ml 100% C3F8 at a time in retrobulbar anesthesia. The patient was instructed to maintain face down positioning for 2 days. \\nResults: We evaluated the visual acuity, central retinal thickness (CRT), and central pigment epithelial detachment (PED) thickness for 2 years. The visual acuity was increasing gradually from 6/18 to 6/6 in the first year. The hemorrhage was displaced completely, the CRT and central PED thickness were decreased. In the second year the patient had recurrence of PCV with serous retinal detachment and treated with intravitreal aflibercept. \\nConclusion: Combined treatment of intravitreal t-PA, ranibizumab, and C3F8 can be used as a beneficial therapy for PCV.\",\"PeriodicalId\":33128,\"journal\":{\"name\":\"IJRETINA International Journal of Retina\",\"volume\":\"91 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-08-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"IJRETINA International Journal of Retina\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35479/IJRETINA.2018.VOL001.ISS002.46\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJRETINA International Journal of Retina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35479/IJRETINA.2018.VOL001.ISS002.46","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
简介:报告一例PCV已成功治疗的玻璃体内注射t-PA,雷尼单抗和气动置换。方法:65岁男性,右眼视力模糊。未发现全身性异常。初始视力RE为6/18。眼底镜检查显示后极黄斑下出血。OCTA、FA和ICG证实PCV的诊断。我们在球后麻醉下进行前房穿刺和玻璃体内注射0.05 ml t-PA、0.05 ml雷尼单抗和0.3 ml 100% C3F8。嘱患者保持面朝下体位2天。结果:我们对视力、视网膜中央厚度(CRT)和中央色素上皮脱离(PED)厚度进行了为期2年的评估。第一年视力由6/18逐渐提高到6/6。出血完全移位,CRT和中央PED厚度减少。在第二年,患者复发的PCV,浆液性视网膜脱离和治疗玻璃体内阿伯西普。结论:玻璃体内注射t-PA、雷尼单抗、C3F8联合治疗可作为治疗PCV的有效方法。
Introduction: to report a case of PCV that has been successfully treated with intravitreal injection of t-PA, ranibizumab, and pneumatic displacement.
Method: A 65 years old man presented with blurred vision of his right eye. No systemic abnormalities were found. Initial visual acuity RE was 6/18. Funduscopy examination showed submacular hemorrhage in posterior pole. OCTA, FA and ICG confirmed the diagnosis of PCV. We performed anterior chamber paracentesis and intravitreal injection of 0,05 ml t-PA, 0,05 ml ranibizumab, and 0,3 ml 100% C3F8 at a time in retrobulbar anesthesia. The patient was instructed to maintain face down positioning for 2 days.
Results: We evaluated the visual acuity, central retinal thickness (CRT), and central pigment epithelial detachment (PED) thickness for 2 years. The visual acuity was increasing gradually from 6/18 to 6/6 in the first year. The hemorrhage was displaced completely, the CRT and central PED thickness were decreased. In the second year the patient had recurrence of PCV with serous retinal detachment and treated with intravitreal aflibercept.
Conclusion: Combined treatment of intravitreal t-PA, ranibizumab, and C3F8 can be used as a beneficial therapy for PCV.